Publications by authors named "A Laadem"
Purpose: To evaluate DS-6157a, an antibody-drug conjugate targeting G protein-coupled receptor 20 (GPR20), in gastrointestinal stromal tumors (GIST).
Patients And Methods: In this phase I multicenter, open-label, multiple-dose study, patients with previously treated advanced GIST received intravenous DS-6157a on Day 1 of 21-day cycles, with a starting dose of 1.6 mg/kg.
Article Synopsis
- Racial disparities in cancer outcomes are well-documented, with Black patients facing the highest death rates, but limited research exists on myelodysplastic syndromes (MDS) specifically.
- This study analyzed demographic, clinical, socioeconomic factors, and survival outcomes between Black and White MDS patients using data from 37,562 cases diagnosed between 2001 and 2013.
- Results showed that Black patients had longer overall survival compared to White patients, although this varies by specific MDS subtype and should be interpreted carefully.
Article Synopsis
- β-Thalassemia is a genetic blood disorder that causes issues with hemoglobin production, leading to the need for regular blood transfusions and potential complications like iron overload.
- Luspatercept is the first approved therapy in the U.S. that helps improve anemia in adult patients with β-thalassemia who rely on these transfusions, showing effective dosage and reduced transfusion needs.
- Studies indicate that luspatercept has a favorable safety profile and its administration is based on body weight, making it a promising alternative therapy for managing β-thalassemia.
Article Synopsis
- Luspatercept is a fusion protein that helps improve late-stage red blood cell development and has been studied in 260 patients with anemia from myelodysplastic syndromes.
- The drug has predictable pharmacokinetics and its dosage varies from 0.125 to 1.75 mg/kg, with body weight being the main factor for determining the correct dose.
- The findings indicate that higher serum levels of luspatercept improve the chances of patients achieving transfusion independence and experiencing fewer severe side effects, supporting a dose range of 1.0 to 1.75 mg/kg for effective long-term treatment.
Background: Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients.
Methods: In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with transfusion-dependent β-thalassemia to receive best supportive care plus luspatercept (at a dose of 1.